LONCASTUXIMAB TESIRINE-LPYL for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 8 adverse event reports in the FDA FAERS database where LONCASTUXIMAB TESIRINE-LPYL was used for Diffuse large b-cell lymphoma refractory.
Most Reported Side Effects for LONCASTUXIMAB TESIRINE-LPYL
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 32 | 15.8% | 32 | 3 |
| Rash | 17 | 8.4% | 2 | 2 |
| Pleural effusion | 14 | 6.9% | 3 | 4 |
| Fatigue | 13 | 6.4% | 0 | 1 |
| Oedema | 13 | 6.4% | 3 | 1 |
| Photosensitivity reaction | 12 | 5.9% | 3 | 1 |
| Disease progression | 8 | 4.0% | 5 | 0 |
| Neutropenia | 8 | 4.0% | 1 | 1 |
| Diarrhoea | 7 | 3.5% | 0 | 1 |
| Infection | 7 | 3.5% | 3 | 2 |
| Oedema peripheral | 7 | 3.5% | 3 | 4 |
| Pericardial effusion | 7 | 3.5% | 1 | 2 |
| Thrombocytopenia | 7 | 3.5% | 2 | 2 |
| Diffuse large b-cell lymphoma | 6 | 3.0% | 6 | 1 |
| Hepatotoxicity | 5 | 2.5% | 0 | 0 |
Other Indications for LONCASTUXIMAB TESIRINE-LPYL
Other Drugs Used for Diffuse large b-cell lymphoma refractory
RITUXIMAB (667)
EPCORITAMAB-BYSP (353)
AXICABTAGENE CILOLEUCEL (336)
BENDAMUSTINE (283)
CYCLOPHOSPHAMIDE (226)
POLATUZUMAB VEDOTIN (223)
ETOPOSIDE (165)
POLATUZUMAB VEDOTIN-PIIQ (158)
GEMCITABINE (147)
LENALIDOMIDE (143)